Investing in our common stock involves a high degree of risk, and you should carefully consider the risks and uncertainties described below … if any of the following risks or uncertainties actually occurs, our business, financial condition or results of operations would likely suffer, possibly materially; adverse pricing limitations or a delay in obtaining coverage and reimbursement would decrease our future net product revenues and harm our business; our ability to achieve and sustain profitability depends on the extent to which we can continue to increase our revenue and control our costs in order to, among other things, counter any unforeseen difficulties, complications or other unknown factors that may impair future revenue or require additional expenditures; we face intense competition for our personnel from our competitors and other companies throughout our industry … if we are unable to hire and retain qualified personnel, there could be a material adverse effect on our business; our supply chain for sourcing raw materials and manufacturing drug product ready for distribution is a multi‐step international endeavor … any supply disruptions could disrupt sales of our products and/or the timing of our clinical trials; we maintain and rely extensively on information technology systems and network infrastructures for the effective operation of our business … a disruption, infiltration or failure of our information technology systems … could cause breaches of data security and loss of critical data, which in turn could materially adversely affect our business and subject us to both private and governmental causes of action; if we fail to comply with domestic or foreign laws could result in various adverse consequences, including the possible delay in approval or refusal to approve a product, recalls, seizures, withdrawal of an approved product from the market, the imposition of civil or criminal penalties; we have expanded and are continuing to expand our global operations over the past several years in order to market orkambi and kalydeco and expand our research and development capabilities; if our competitors bring drugs with superior product profiles to market, our drugs may not be competitive and our revenues could decline; if physicians and patients do not accept our drugs, or if patients do not remain on treatment or comply with the prescribed dosing regimen, our product revenues would be materially harmed in future periods; and if our facilities were to experience a catastrophic loss, due to a fire, earthquake or similar event, our operations could be seriously harmed.